Advice
following a full submission:
infliximab (Remicade®) is accepted for restricted use within NHS Scotland.
Indication under review: Treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies
SMC restriction: as an alternative to ciclosporin in patients with acute, severe paediatric ulcerative colitis (rescue therapy) who are steroid refractory.
Open-label, uncontrolled data indicate that infliximab induces remission of moderate to severe active ulcerative colitis in paediatric patients.
Download detailed advice151KB (PDF)
Medicine details
- Medicine name:
- infliximab (Remicade)
- SMC ID:
- 854/13
- Indication:
- treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
- Pharmaceutical company
- MSD
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 11 March 2013